EUVIMEDEUVIMED entdecken
Open Access

FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells

Abdulghani A Naeem, Saud A Abdulsamad, Hao Zeng, Gang He, Xi Jin, Jiacheng Zhang, Bandar T Alenezi, Hongwen Ma, Philip S Rudland, Youqiang Ke

International Journal of Oncology · 21.12.2023 · 64 (2)

DOI: 10.3892/ijo.2023.5606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Oncology, online erschienen am 21.12.2023. Verfasst von Abdulghani A Naeem und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fatty acid‑binding protein 5 (FABP5) and androgen receptor (AR) are critical promoters of prostate cancer. In the present study, the effects of knocking out the FABP5 or AR genes on malignant characteristics of prostate cancer cells were investigated, and changes in the expression of certain key proteins in the FABP5 (or AR)‑peroxisome proliferator activated receptor‑γ (PPARγ)‑vascular endothelial growth factor (VEGF) signaling pathway were monitored. The results obtained showed that FABP5‑ or AR‑knockout (KO) led to a marked suppression of the malignant characteristics of the cells, in part, through disrupting this signaling pathway. Moreover, FABP5 and AR are able to interact with each other to regulate this pathway, with FABP5 controlling the dominant AR splicing variant 7 (ARV7), and AR, in return, regulates the expression of FABP5. Comparisons of the RNA profiles revealed the existence of numerous differentially expressed genes (DEGs) comparing between the parental and the FABP5‑ or AR‑KO cells. The six most abundant changes in DEGs were found to be attributable to the transition from androgen‑responsive to androgen‑unresponsive, castration‑resistant prostate cancer (CRPC) cells. These findings have provided novel insights into the complex molecular pathogenesis of CRPC cells, and have demonstrated that interactions between FABP5 and AR contribute to the transition of prostate cancer cells to an androgen‑independent state. Moreover, gene enrichment analysis revealed that the most highly enriched biological processes associated with the DEGs included those responsive to fatty acids, cholesterol and sterol biosynthesis, as well as to lipid and fatty acid transportation. Since these pathways regulated by FABP5 or AR may be crucial in terms of transducing signals for cancer cell progression, targeting FABP5, AR and their associated pathways, rather than AR alone, may provide a new avenue for the development of therapeutic strategies geared towards suppressing the malignant progression to CRPC cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, AndrogenProstatic Neoplasms, Castration-ResistantMaleHumansAndrogensVascular Endothelial Growth Factor ACell Line, TumorGene Expression Regulation, NeoplasticFatty Acid-Binding Proteins

Stichwörter der Autor:innen

ARARV7CRPCDEGsFABP5gene KOprostate cancer

Substanzen

Receptors, AndrogenAndrogensVascular Endothelial Growth Factor AFABP5 protein, humanFatty Acid-Binding Proteins

Autor:innen und Institutionen

  • Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
  • Department of Molecular and Clinical Cancer Medicine, Liverpool University, Liverpool L69 3PX, UK.
  • Department of Biochemistry and Systems Biology, Liverpool University, Liverpool L69 3PX, UK.

Zitieren

APA

Naeem, A. A., Abdulsamad, S. A., Zeng, H., He, G., Jin, X., Zhang, J., Alenezi, B. T., Ma, H., Rudland, P. S., & Ke, Y. (2023). FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells. International Journal of Oncology, 64(2). https://doi.org/10.3892/ijo.2023.5606

Vancouver

Naeem AA, Abdulsamad SA, Zeng H, He G, Jin X, Zhang J, et al. FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells. International Journal of Oncology. 2023;64(2). doi:10.3892/ijo.2023.5606

BibTeX
@article{Naeem2023,
  author = {Naeem, Abdulghani A and Abdulsamad, Saud A and Zeng, Hao and He, Gang and Jin, Xi and Zhang, Jiacheng and Alenezi, Bandar T and Ma, Hongwen and Rudland, Philip S and Ke, Youqiang},
  title = {FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells},
  journal = {International Journal of Oncology},
  year = {2023},
  volume = {64},
  number = {2},
  doi = {10.3892/ijo.2023.5606}
}
Kostenlos starten →